Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial

Objectives This post-hoc analysis of CM310AD005 conductedaimed to analyze the efficacy and safety of stapokibart in adults with moderate-to-severe atopic dermatitis (AD) with and without prior systemic treatment.Methods In CM310AD005, eligible patients were randomized 1:1 to receive stapokibart 600...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Yan Zhao, Litao Zhang, Liming Wu, Bin Yang, Jinyan Wang, Yumei Li, Qingchun Diao, Jingyi Li, Qing Sun, Xiaohong Zhu, Xiaoyong Man, Lihua Wang, Yanyan Feng, Tao Cai, Huiming Zeng, Linfeng Li, Jianyun Lu, Hong Ren, Fuqiu Li, Qianjin Lu, Xiaohua Tao, Rong Xiao, Chao Ji, Wenjie Zhao, Wei Chu, Bo Chen, Jianzhong Zhang
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Taylor & Francis Group 2026-12-01
Seri Bilgileri:	Journal of Dermatological Treatment
Konular:	Stapokibart atopic dermatitis systemic treatment novel therapy biologics
Online Erişim:	https://www.tandfonline.com/doi/10.1080/09546634.2026.2670890
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!